Abstract

Aim: This study aimed to evaluate the diagnostic value of serum amyloid A (SAA) by comparing it with conventional acute phase markers (APMs), such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fibrinogen, in patients experiencing pain related to chronic inflammatory and gallbladder diseases.

Materials and Methods: We retrospectively examined data retrieved from the medical records of 601 patients diagnosed with chronic inflammatory disease, gallbladder stones who underwent cholecystectomy between January 2020 and June 2023. We compared serum levels of ESR, SAA, CRP, and fibrinogen during episodes of pain.

Results: The study population consisted of 601 patients, of whom 401 (66.72%) were female and 200 (33.28%) were male. The mean age was 48.74±17.20 years for females and 46.62±17.52 years for males. Serum SAA, CRP, ESR, and fibrinogen levels showed a statistically significant positive correlation. The most significant correlation was between SAA and CRP. However, there was no rise in CRP or other acute phase markers (APMs), even though SAA rose in about one-fourth of the patients (24.7%).

Conclusion: Monitoring chronic inflammatory diseases with SAA is thought to be useful for detecting subclinical inflammation and underlying chronic inflammatory diseases. It may also prevent the development of amyloidosis and therefore morbidity and mortality.

Keywords: Chronic inflammatory diseases, serum amyloid A, C-reactive protein, erythrocyte sedimentation rate, fibrinogen

Copyright and license

Copyright © 2025 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Avcı AO. The role of serum amyloid A as an inflammatory biomarker in patients with chronic inflammatory conditions. Northwestern Med J. 2025;5(3):145-50. https://doi.org/10.54307/2025.NWMJ.144

References

  1. Gulhar R, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
  2. Mantovani A, Garlanda C. Humoral Innate Immunity and Acute-Phase Proteins. N Engl J Med. 2023; 388(5): 439-52. https://doi.org/10.1056/NEJMra2206346
  3. Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of Inflammation. Methods Mol Biol. 2018; 1803: 57-79. https://doi.org/10.1007/978-1-4939-8549-4_5
  4. Zhang Y, Zhang J, Sheng H, Li H, Wang R. Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem. 2019; 90: 25-80. https://doi.org/10.1016/bs.acc.2019.01.002
  5. Thorne J, Clark D, Geldenhuys L, More K, Vinson A, Tennankore K. Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management. Kidney Med. 2022; 4(8): 100504. https://doi.org/10.1016/j.xkme.2022.100504
  6. Sack GH. Serum amyloid A - a review. Mol Med. 2018; 24(1): 46. https://doi.org/10.1186/s10020-018-0047-0
  7. Çakan M, Karadağ ŞG, Tanatar A, Sönmez HE, Ayaz NA. The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods. J Clin Rheumatol. 2021; 27(1): 1-4. https://doi.org/10.1097/RHU.0000000000001134
  8. Gutt C, Schläfer S, Lammert F. The Treatment of Gallstone Disease. Dtsch Arztebl Int. 2020; 117(9): 148-58. https://doi.org/10.3238/arztebl.2020.0148
  9. Matsuda S, Nishikata M, Takai K, et al. An Unusual Case of Acute Cholecystitis with Amyloidosis: A Case Report and Literature Review. Intern Med. 2019; 58(6): 803-7. https://doi.org/10.2169/internalmedicine.1805-18
  10. Kwon AH, Tsuji K, Yamada H, Okazaki K, Sakaida N. Amyloidosis of the gallbladder mimicking gallbladder cancer. J Gastroenterol. 2007; 42(3): 261-4. https://doi.org/10.1007/s00535-006-1987-7
  11. Sack GH Jr. Serum amyloid A - a review. Mol Med. 2018; 24(1): 46. https://doi.org/10.1186/s10020-018-0047-0
  12. Dobson DA, Fish RJ, de Vries PS, Morrison AC, Neerman-Arbez M, Wolberg AS. Regulation of fibrinogen synthesis. Thromb Res. 2024; 242: 109134. https://doi.org/10.1016/j.thromres.2024.109134
  13. Pathak A, Agrawal A. Evolution of C-Reactive Protein. Front Immunol. 2019; 10: 943. https://doi.org/10.3389/fimmu.2019.00943
  14. Sorić Hosman I, Kos I, Lamot L. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. Front Immunol. 2021; 11: 631299. https://doi.org/10.3389/fimmu.2020.631299
  15. Hwang YG, Balasubramani GK, Metes ID, Levesque MC, Bridges SL, Moreland LW. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016; 18(1): 108. https://doi.org/10.1186/s13075-016-1009-y
  16. Hu QL, Fu S, Huang R, Zhang L, Wu LF, Lv YJ. The Value of Serum Amyloid A in the Diagnosis and Management of Ankylosing Spondylitis. Int J Gen Med. 2021; 14: 2715-9. https://doi.org/10.2147/IJGM.S310677
  17. Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol. 2003; 21(4): 509-14.
  18. Sözel H, Yılmaz F, Avşar E, Maştaoğlu E, Alemdar MS, Bora F. Erişkin Ailevi Akdeniz Ateşi Hastalarında Ataksız Dönemdeki Serum Amiloid A’nın Diğer İnflamatuar Belirteçlerle Korelasyonu. Osmangazi Tıp Dergisi. 2021; 43(6): 609-16. https://doi.org/10.20515/otd.938690
  19. Lachmann HJ, Sengül B, Yavuzşen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006; 45(6): 746-50. https://doi.org/10.1093/rheumatology/kei279